Antiangiogenic activities of 2,5-dimethyl-celecoxib on the tumor vasculature

Jenilyn J. Virrey, Zhi Liu, Hee Yeon Cho, Adel Kardosh, Encouse B. Golden, Stan G. Louie, Kevin J. Gaffney, Nicos A. Petasis, Axel H. Schönthal, Thomas C. Chen, Florence M. Hofman

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Our laboratory has previously shown that a novel compound, 2,5-dimethyl-celecoxib (DMC), which is structurally similar to the cyclooxygenase-2 (COX-2) inhibitor celecoxib but lacks the COX-2-inhibitory function, mimics the antitumor effects of celecoxib. Most studies on DMC, however, focused on its effects on tumor cells. Here, we investigated the activities of DMC as an antiangiogenic agent in both in vitro and in vivo systems. Using primary cultures of human glioma specimens, we found that DMC treatment was cytotoxic to tumor-associated brain endothelial cells (TuBEC), which was mediated through the endoplasmic reticulum stress pathway. In contrast, confluent cultures of quiescent human BEC did not undergo cell death. DMC potently suppressed the proliferation and migration of the TuBEC. DMC caused no apparent effects on the secretion of vascular endothelial growth factor and interleukin-8 but inhibited the secretion of endothelin-1 in tumor-associated EC. DMC treatment of glioma xenografts in mice resulted in smaller tumors with a pronounced reduction in microvessel density compared with untreated mice. In vitro and in vivo analyses confirmed that DMC has antivascular activity. Considering that DMC targets both tumor cells and tumor-associated ECs, this agent is a promising anticancer drug.

Original languageEnglish (US)
Pages (from-to)631-641
Number of pages11
JournalMolecular cancer therapeutics
Volume9
Issue number3
DOIs
StatePublished - Mar 1 2010
Externally publishedYes

Fingerprint

Celecoxib
Neoplasms
Brain Neoplasms
Glioma
Endothelial Cells
2,5-dimethylcelecoxib
Endoplasmic Reticulum Stress
Angiogenesis Inhibitors
Cyclooxygenase 2 Inhibitors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Virrey, J. J., Liu, Z., Cho, H. Y., Kardosh, A., Golden, E. B., Louie, S. G., ... Hofman, F. M. (2010). Antiangiogenic activities of 2,5-dimethyl-celecoxib on the tumor vasculature. Molecular cancer therapeutics, 9(3), 631-641. https://doi.org/10.1158/1535-7163.MCT-09-0652

Antiangiogenic activities of 2,5-dimethyl-celecoxib on the tumor vasculature. / Virrey, Jenilyn J.; Liu, Zhi; Cho, Hee Yeon; Kardosh, Adel; Golden, Encouse B.; Louie, Stan G.; Gaffney, Kevin J.; Petasis, Nicos A.; Schönthal, Axel H.; Chen, Thomas C.; Hofman, Florence M.

In: Molecular cancer therapeutics, Vol. 9, No. 3, 01.03.2010, p. 631-641.

Research output: Contribution to journalArticle

Virrey, JJ, Liu, Z, Cho, HY, Kardosh, A, Golden, EB, Louie, SG, Gaffney, KJ, Petasis, NA, Schönthal, AH, Chen, TC & Hofman, FM 2010, 'Antiangiogenic activities of 2,5-dimethyl-celecoxib on the tumor vasculature', Molecular cancer therapeutics, vol. 9, no. 3, pp. 631-641. https://doi.org/10.1158/1535-7163.MCT-09-0652
Virrey, Jenilyn J. ; Liu, Zhi ; Cho, Hee Yeon ; Kardosh, Adel ; Golden, Encouse B. ; Louie, Stan G. ; Gaffney, Kevin J. ; Petasis, Nicos A. ; Schönthal, Axel H. ; Chen, Thomas C. ; Hofman, Florence M. / Antiangiogenic activities of 2,5-dimethyl-celecoxib on the tumor vasculature. In: Molecular cancer therapeutics. 2010 ; Vol. 9, No. 3. pp. 631-641.
@article{0cf02da119b448e494b7cfac8fb1b0fe,
title = "Antiangiogenic activities of 2,5-dimethyl-celecoxib on the tumor vasculature",
abstract = "Our laboratory has previously shown that a novel compound, 2,5-dimethyl-celecoxib (DMC), which is structurally similar to the cyclooxygenase-2 (COX-2) inhibitor celecoxib but lacks the COX-2-inhibitory function, mimics the antitumor effects of celecoxib. Most studies on DMC, however, focused on its effects on tumor cells. Here, we investigated the activities of DMC as an antiangiogenic agent in both in vitro and in vivo systems. Using primary cultures of human glioma specimens, we found that DMC treatment was cytotoxic to tumor-associated brain endothelial cells (TuBEC), which was mediated through the endoplasmic reticulum stress pathway. In contrast, confluent cultures of quiescent human BEC did not undergo cell death. DMC potently suppressed the proliferation and migration of the TuBEC. DMC caused no apparent effects on the secretion of vascular endothelial growth factor and interleukin-8 but inhibited the secretion of endothelin-1 in tumor-associated EC. DMC treatment of glioma xenografts in mice resulted in smaller tumors with a pronounced reduction in microvessel density compared with untreated mice. In vitro and in vivo analyses confirmed that DMC has antivascular activity. Considering that DMC targets both tumor cells and tumor-associated ECs, this agent is a promising anticancer drug.",
author = "Virrey, {Jenilyn J.} and Zhi Liu and Cho, {Hee Yeon} and Adel Kardosh and Golden, {Encouse B.} and Louie, {Stan G.} and Gaffney, {Kevin J.} and Petasis, {Nicos A.} and Sch{\"o}nthal, {Axel H.} and Chen, {Thomas C.} and Hofman, {Florence M.}",
year = "2010",
month = "3",
day = "1",
doi = "10.1158/1535-7163.MCT-09-0652",
language = "English (US)",
volume = "9",
pages = "631--641",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Antiangiogenic activities of 2,5-dimethyl-celecoxib on the tumor vasculature

AU - Virrey, Jenilyn J.

AU - Liu, Zhi

AU - Cho, Hee Yeon

AU - Kardosh, Adel

AU - Golden, Encouse B.

AU - Louie, Stan G.

AU - Gaffney, Kevin J.

AU - Petasis, Nicos A.

AU - Schönthal, Axel H.

AU - Chen, Thomas C.

AU - Hofman, Florence M.

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Our laboratory has previously shown that a novel compound, 2,5-dimethyl-celecoxib (DMC), which is structurally similar to the cyclooxygenase-2 (COX-2) inhibitor celecoxib but lacks the COX-2-inhibitory function, mimics the antitumor effects of celecoxib. Most studies on DMC, however, focused on its effects on tumor cells. Here, we investigated the activities of DMC as an antiangiogenic agent in both in vitro and in vivo systems. Using primary cultures of human glioma specimens, we found that DMC treatment was cytotoxic to tumor-associated brain endothelial cells (TuBEC), which was mediated through the endoplasmic reticulum stress pathway. In contrast, confluent cultures of quiescent human BEC did not undergo cell death. DMC potently suppressed the proliferation and migration of the TuBEC. DMC caused no apparent effects on the secretion of vascular endothelial growth factor and interleukin-8 but inhibited the secretion of endothelin-1 in tumor-associated EC. DMC treatment of glioma xenografts in mice resulted in smaller tumors with a pronounced reduction in microvessel density compared with untreated mice. In vitro and in vivo analyses confirmed that DMC has antivascular activity. Considering that DMC targets both tumor cells and tumor-associated ECs, this agent is a promising anticancer drug.

AB - Our laboratory has previously shown that a novel compound, 2,5-dimethyl-celecoxib (DMC), which is structurally similar to the cyclooxygenase-2 (COX-2) inhibitor celecoxib but lacks the COX-2-inhibitory function, mimics the antitumor effects of celecoxib. Most studies on DMC, however, focused on its effects on tumor cells. Here, we investigated the activities of DMC as an antiangiogenic agent in both in vitro and in vivo systems. Using primary cultures of human glioma specimens, we found that DMC treatment was cytotoxic to tumor-associated brain endothelial cells (TuBEC), which was mediated through the endoplasmic reticulum stress pathway. In contrast, confluent cultures of quiescent human BEC did not undergo cell death. DMC potently suppressed the proliferation and migration of the TuBEC. DMC caused no apparent effects on the secretion of vascular endothelial growth factor and interleukin-8 but inhibited the secretion of endothelin-1 in tumor-associated EC. DMC treatment of glioma xenografts in mice resulted in smaller tumors with a pronounced reduction in microvessel density compared with untreated mice. In vitro and in vivo analyses confirmed that DMC has antivascular activity. Considering that DMC targets both tumor cells and tumor-associated ECs, this agent is a promising anticancer drug.

UR - http://www.scopus.com/inward/record.url?scp=77949714264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949714264&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-09-0652

DO - 10.1158/1535-7163.MCT-09-0652

M3 - Article

VL - 9

SP - 631

EP - 641

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 3

ER -